Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase lll Clinical

Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring
Committee to Continue Pivotal Phase lll Clinical Trial for Firdapse(TM)

CORAL GABLES, Fla., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neuromuscular and neurological diseases and disorders, announced
today that, at a recently held meeting, the independent Data Monitoring
Committee (DMC) overseeing the Company's ongoing pivotal Phase III clinical
trial in the United States and Europe evaluating Firdapse™ for the treatment
of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the Company
continue the trial as planned based on the committee's review of safety and
clinical data from the trial.

The DMC is a group of experts responsible for the independent review of
accumulated, unblinded clinical safety and efficacy data obtained in the
Company's clinical trial, in order to safeguard the interests and safety of
participants and future patients. The DMC considers study-specific data, as
well as relevant background knowledge about the disease, test agent or patient
population under study.

The Firdapse™ Phase III clinical trial is designed as a randomized,
double-blind, placebo-controlled, discontinuation trial enrolling 36 patients
diagnosed with LEMS at sites in the U.S. and Europe. To accomplish this, the
Company, in addition to the 7 active sites at the time of acquisition, has
initiated 12 additional sites and expects to initiate shortly an additional 6
sites in the U.S., Europe, Canada and South America. The Company expects to
complete enrollment in the trial about the end of the fourth quarter of 2013
and to announce top line data from the trial during the second quarter of
2014.

About LEMS

Lambert-Eaton Myasthenic Syndrome, or LEMS, is a rare autoimmune disorder
characterized by muscle weakness of the limbs. The disease is caused by an
autoimmune reaction where antibodies are formed against the connection between
nerves and the muscles they supply. Often, LEMS is associated with an
underlying malignancy, most commonly small-cell lung cancer, and in some
individuals, LEMS is the first symptom of such malignancy. LEMS generally
affects the extremities, especially the legs. As the disease most affects the
parts of limbs closest to the trunk, difficulties with climbing stairs or
rising from a sitting position are commonly noted. Physical exercise and high
temperatures tend to worsen the symptoms. Other symptoms occasionally seen
include weakness of the muscles of the mouth, throat, and eyes. Individuals
affected with LEMS also may have a disruption of the autonomic nervous system,
including dry mouth, constipation, blurred vision, impaired sweating, and/or
hypotension.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of novel prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial and recently received "Breakthrough Therapy Designation" from the U.S.
Food and Drug Administration (FDA). Catalyst is also developing a potentially
safer and more potent vigabatrin analog (designated CPP-115) to treat
infantile spasms, and epilepsy, as well as other neurological conditions
associated with reduced GABAergic signaling, like post-traumatic stress
disorder and Tourette Syndrome.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including the timing of completion of
Catalyst's currently ongoing Phase III trial of Firdapse™, whether the Phase
III trial will be successful, whether the receipt of breakthrough therapy
designation for Firdapse™ will expedite the development and review of
Firdapse™ by the FDA or the likelihood that the product will be found to be
safe and effective, whether an NDA for Firdapse™ will ever be accepted for
filing by the FDA, the timing of any such NDA filing or acceptance, whether
any of Catalyst's product candidates will ever be approved for
commercialization or successfully commercialized, and those other factors
described in Catalyst's Annual Report on Form 10-K for the fiscal year 2012
and other filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com
 
Press spacebar to pause and continue. Press esc to stop.